Independent Advisor Alliance Purchases 10,706 Shares of Merck & Co., Inc. $MRK

Posted by Francis Steltz on May 13th, 2026

Independent Advisor Alliance increased its stake in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 12.1% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 98,968 shares of the company’s stock after acquiring an additional 10,706 shares during the period. Independent Advisor Alliance’s holdings in Merck & Co., Inc. were worth $10,417,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. United Financial Planning Group LLC bought a new position in shares of Merck & Co., Inc. during the 3rd quarter worth approximately $31,000. Wealth Watch Advisors INC acquired a new stake in Merck & Co., Inc. during the 3rd quarter valued at $34,000. Dunhill Financial LLC increased its holdings in Merck & Co., Inc. by 83.0% during the 3rd quarter. Dunhill Financial LLC now owns 419 shares of the company’s stock valued at $35,000 after purchasing an additional 190 shares in the last quarter. Silicon Valley Capital Partners increased its holdings in Merck & Co., Inc. by 160.5% during the 3rd quarter. Silicon Valley Capital Partners now owns 422 shares of the company’s stock valued at $35,000 after purchasing an additional 260 shares in the last quarter. Finally, J.Safra Asset Management Corp increased its holdings in Merck & Co., Inc. by 53.6% during the 3rd quarter. J.Safra Asset Management Corp now owns 450 shares of the company’s stock valued at $38,000 after purchasing an additional 157 shares in the last quarter. Institutional investors own 76.07% of the company’s stock.

Analyst Upgrades and Downgrades

MRK has been the subject of a number of recent analyst reports. UBS Group raised their price target on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a report on Monday, April 13th. Weiss Ratings reissued a “hold (c+)” rating on shares of Merck & Co., Inc. in a research note on Friday, May 1st. Citigroup assumed coverage on Merck & Co., Inc. in a research note on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 target price for the company. Wells Fargo & Company lowered their target price on Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Finally, Zacks Research raised Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 17th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and a consensus target price of $128.18.

Get Our Latest Research Report on MRK

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

Positive Sentiment: Merck highlighted new long-term oncology data and more than 100 ASCO 2026 abstracts spanning over 25 cancer types, underscoring the depth of its KEYTRUDA-driven pipeline and giving investors fresh reasons to stay constructive on the growth outlook. Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026
Positive Sentiment: Merck expanded KEYTRUDA collaborations with Erasca and Inhibrx, including a new trial collaboration and encouraging interim Phase 2 results that could advance into Phase 3, signaling continued external validation of its oncology franchise. Merck Broadens KEYTRUDA Collaborations As Patent Expiry Pressure Builds
Positive Sentiment: Analysts and commentary continue to point to Merck’s growth drivers, with reports emphasizing pipeline strength and Keytruda-related momentum after the company beat quarterly revenue expectations. Merck (MRK) Tops Quarterly Sales Forecasts as Keytruda Drives Growth
Neutral Sentiment: Citi reinstated Merck with a Neutral rating and a $125 price target, suggesting limited near-term upside despite a still-supportive valuation backdrop. Analyst Reinstates Merck (MRK) with ‘Neutral’ Rating, $125 Price Target
Neutral Sentiment: Zacks noted that investors are weighing Merck’s earnings beat against pipeline setbacks and weakness in Gardasil, creating a mixed fundamental picture rather than a clean catalyst. Merck Stock Down 7% in a Month: Should Investors Hold or Exit?
Negative Sentiment: Merck continues to face pressure from patent-expiry concerns and commentary about slowing parts of the portfolio, which can limit enthusiasm even after recent positive trial and sales updates. Merck Broadens KEYTRUDA Collaborations As Patent Expiry Pressure Builds

Merck & Co., Inc. Stock Up 1.0%

NYSE:MRK opened at $112.40 on Wednesday. Merck & Co., Inc. has a 12-month low of $73.31 and a 12-month high of $125.14. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. The firm has a market capitalization of $277.60 billion, a P/E ratio of 31.66, a P/E/G ratio of 2.51 and a beta of 0.18. The stock’s fifty day simple moving average is $116.47 and its 200-day simple moving average is $108.83.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. During the same period last year, the company earned $2.22 EPS. The firm’s revenue was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Equities research analysts expect that Merck & Co., Inc. will post 5.16 earnings per share for the current year.

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.